Outlook Therapeutics (OTLK) announced that Russell Trenary has stepped down as the company’s president and CEO, effective immediately. Lawrence ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...

Fintel reports that on December 2, 2024, Chardan Capital downgraded their outlook for Outlook Therapeutics (NasdaqCM:OTLK) from Buy to Neutral. Analyst Price Forecast Suggests 1,865.37% Upside As of ...

On Friday, Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $1.97 which represents a slight increase of $0.27 or 15.88% from the prior close of $1.7. The stock opened at $1 ...

Outlook Therapeutics (OTLK) stock plunges 81% after clinical trial failure for its wet AMD therapy, ONS-5010. Read more here.

Outlook Therapeutics Inc. (NASDAQ:OTLK) revealed preliminary topline results of NORSE EIGHT, the second of two clinical ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study evaluating ONS-5010 (Lytenava) to treat patients with wet age-related ...

Outlook Therapeutics Inc. (NASDAQ:OTLK) revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients. In the NORSE EIGHT trial ...